SIRT3 and sarcopenia: These findings suggest that 1,25VD3 has the potential to be developed as a therapeutic agent against sarcopenia by promoting muscle cell development, maintenance, and protection against atrophy and apoptosis through the activation of VDR, SIRT1, and SIRT3.